Published in Pharm Res on July 01, 1996
Delivery of therapeutic proteins. J Pharm Sci (2010) 1.58
Preparation and stability of poly(ethylene glycol) (PEG)ylated octreotide for application to microsphere delivery. AAPS PharmSciTech (2003) 0.96
Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study. Protein Sci (2006) 0.95
Interactions between PEG and type I soluble tumor necrosis factor receptor: modulation by pH and by PEGylation at the N terminus. Protein Sci (2002) 0.87
N-terminal protein modification using simple aminoacyl transferase substrates. J Am Chem Soc (2011) 0.86
PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution. J Biomed Mater Res A (2009) 0.85
Hematopoietic properties of granulocyte colony-stimulating factor/immunoglobulin (G-CSF/IgG-Fc) fusion proteins in normal and neutropenic rodents. PLoS One (2014) 0.82
Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b. J Interferon Cytokine Res (2013) 0.79
Prevention of benzyl alcohol-induced aggregation of chymotrypsinogen by PEGylation. J Pharm Pharmacol (2011) 0.77
N-PEGylation of a reverse turn is stabilizing in multiple sequence contexts, unlike N-GlcNAcylation. ACS Chem Biol (2011) 0.77
Site-Specific PEGylation of Therapeutic Proteins. Int J Mol Sci (2015) 0.76
Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): report of an international collaborative study. J Immunol Methods (2014) 0.75
Trehalose Glycopolymer Enhances Both Solution Stability and Pharmacokinetics of a Therapeutic Protein. Bioconjug Chem (2017) 0.75
PEGylated Human Serum Albumin: Review of PEGylation, Purification and Characterization Methods. Adv Pharm Bull (2016) 0.75
Evaluation of in vitro cytotoxic activity of mono-PEGylated StAP3 (Solanum tuberosum aspartic protease 3) forms. Biotechnol Rep (Amst) (2014) 0.75
Site-specific PEGylation of lidamycin and its antitumor activity. Acta Pharm Sin B (2015) 0.75
Fully Synthetic Granulocyte Colony-Stimulating Factor Enabled by Isonitrile-Mediated Coupling of Large, Side-Chain-Unprotected Peptides. J Am Chem Soc (2015) 0.75
Granulocyte colony-stimulating factor (GCSF) fused with Fc Domain produced from E. coli is less effective than Polyethylene Glycol-conjugated GCSF. Sci Rep (2017) 0.75
Nature of the charged-group effect on the stability of the C-peptide helix. Proc Natl Acad Sci U S A (1985) 2.09
Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol Pharmacol (1994) 1.92
Manipulation of the observed kinetic phases in the refolding of denatured ferricytochromes c. J Biol Chem (1983) 1.36
Reversible self-association of bovine growth hormone during equilibrium unfolding. Biochemistry (1986) 1.11
Characterization of an associated equilibrium folding intermediate of bovine growth hormone. Biochemistry (1986) 0.98
Physicochemical basis for the rapid time-action of LysB28ProB29-insulin: dissociation of a protein-ligand complex. Protein Sci (1996) 0.97
Isolation and characterization of a photoaffinity-labeled peptide from the catalytic site of prenyltransferase. Biochemistry (1981) 0.95
Photoaffinity labeling of the catalytic site of prenyltransferase. Biochemistry (1979) 0.94
On the mechanism of the prenyltransferase reaction. Metal ion dependent solvolysis of an allylic pyrophosphate. J Am Chem Soc (1977) 0.93
The effects of alpha-helix on the stability of Asn residues: deamidation rates in peptides of varying helicity. Protein Sci (1999) 0.93
The kinetics of bovine growth hormone folding are consistent with a framework model. J Biol Chem (1987) 0.92
Serine 228 is essential for catalytic activities of 85-kDa cytosolic phospholipase A2. J Biol Chem (1994) 0.91
Kinetic analysis of the folding of human growth hormone. Influence of disulfide bonds. J Biol Chem (1995) 0.89
Recombinant human transforming growth factor-beta 1: expression by Chinese hamster ovary cells, isolation, and characterization. Protein Expr Purif (1993) 0.89
Acid stabilization of insulin. Biochemistry (1993) 0.89
Equilibrium intermediates in the denaturation of human insulin and two monomeric insulin analogs. Biochemistry (1994) 0.88
Equilibrium denaturation of pituitary- and recombinant-derived bovine growth hormone. Biochemistry (1985) 0.86
Evidence for a self-associating equilibrium intermediate during folding of human growth hormone. Biochemistry (1993) 0.86
Specific interaction between beta-lactams and soluble penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus: development of a chromogenic assay. Antimicrob Agents Chemother (1996) 0.85
Protection of amide protons in folding intermediates of ribonuclease A measured by pH-pulse exchange curves. Biochemistry (1985) 0.82
A monoisozymic nucleoside diphosphate kinase capable of complete phosphorylation. J Biol Chem (1981) 0.82
Detection of an equilibrium intermediate in the folding of a monomeric insulin analog. Biochemistry (1992) 0.81
Conformational transitions of frog heart ferricytochrome c. Biochemistry (1982) 0.80
PEGylation prevents the N-terminal degradation of megakaryocyte growth and development factor. Pharm Res (1998) 0.79
Sodium chloride enhances the storage and conformational stability of BDNF and PEG-BDNF. Pharm Res (2001) 0.79
pH-induced conformational states of bovine growth hormone. Biochemistry (1990) 0.78
Multiple conformational states of a new hematopoietic cytokine (megakaryocyte growth and development factor): pH- and urea-induced denaturation. Proteins (1998) 0.78
Disease-coupled specificity in the glycan structures of orosomucoid. Clin Chim Acta (1992) 0.77
Mutation of Arg55/56 to Leu55/Ala56 in insulin-like growth factor-I results in two forms different in disulfide structure and native conformation but similar under reverse-phase conditions. J Protein Chem (1993) 0.77
Inactivation of the Na,K-ATPase by modification of Lys-501 with 4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid (SITS). FEBS Lett (1992) 0.77
Conformational transitions of a cytochrome c having a single thioether bridge. J Biol Chem (1983) 0.76
Refolding and purification of Cephalosporium acremonium deacetoxycephalosporin C synthetase/hydroxylase from granules of recombinant Escherichia coli. Biotechnol Appl Biochem (1996) 0.75
Cystine-rich proteins of human hair: characterization and structure as revealed by reversed-phase and size-exclusion high-performance liquid chromatography. J Chromatogr (1986) 0.75
Proton nuclear magnetic resonance study of the histidine residues of pituitary bovine growth hormone. Biochim Biophys Acta (1989) 0.75
The conformational transition of horse heart porphyrin c. J Biol Chem (1982) 0.75
Determination of local conformational stability in fragment 96-133 of bovine growth hormone by high-resolution H NMR spectroscopy. Biochemistry (1988) 0.75
A method for preparing chelate-cytokine conjugates with retention of protein structure, biological activity, and pharmacokinetic properties. J Immunol Methods (1995) 0.75
Amide proton exchange used to monitor the formation of a stable alpha-helix by residues 3 to 13 during folding of ribonuclease S. J Mol Biol (1984) 0.75
Amide hydrogen exchange of the central B-chain helix within the T- and R-states of insulin hexamers. Biochim Biophys Acta (1994) 0.75
The microfibrillar proteins of human hair: separation by high-performance liquid chromatography and isolation of some proteins enriched in glycine and tyrosine. Anal Biochem (1987) 0.75
Removal of the fluorescent 4-(aminosulfonyl)-2,1,3-benzoxadiazole label from cysteine-containing peptides. J Chromatogr A (1998) 0.75
Reoxidation of reduced bovine growth hormone from a stable secondary structure. Biochemistry (1986) 0.75
The effect of methylation on cytochrome c fragment complementation. J Biol Chem (1981) 0.75